Zeng QL, Yu ZJ, Ji F, et al. - Researchers sought to report the safety and effectiveness results regarding the administration of tenofovir alafenamide fumarate (TAF) during pregnancy for the prevention of mother-to-child transmission (MTCT) of hepatitis B virus (HBV). This multicenter prospective observational study was performed enrolling pregnant women with HBV DNA levels higher than 200,000 IU/ml. The women received TAF or tenofovir disoproxil fumarate (TDF) from gestational weeks 24-35 to delivery and were followed until postpartum month 6. Immunoprophylaxis was provided to infants. The TAF and TDF groups enrolled 116 and 116 mothers, along with birth of 117 and 116 infants, respectively. Overall outcomes suggest antiviral prophylaxis with TAF to be generally safe for both mothers and infants and reduction of the MTCT rate to 0% in correlation with its receipt.